How has Stoke Therapeutics, Inc.'s long-term marketable securities changed year-over-year?

Stoke Therapeutics, Inc.'s long-term marketable securities increased by 193.5% year-over-year, from $22.99M to $67.48M.

Stoke Therapeutics, Inc. STOK Long-term marketable securities

Long-term marketable securities at other companies

Ionis PharmaceuticalsIONS

——

Praxis Precision Medicines, Inc.PRAX

——

Royalty PharmaRPRX

——

Other financials

Income statement

See full

Revenue$6.2M-96.1%

Operating income-$53.4M-148%

Net income-$50.0M-144%

EPS (diluted)-$0.79-142%

Balance sheet

See full

Cash & equivalents$155.7M-43.4%

Total debt$3.4M-42.5%

Total equity$394.9M+12.8%

Total assets$443.3M+8.9%

Cash flow

See full

Operating cash flow-$60.6M-146%

CapEx$353.0K+132%

Free cash flow-$60.9M-146%

Valuation

See full

Market cap$1.89B+436%

Profitability

See full

Operating margin-577.5%-597pp

Net margin-529.2%-556pp

FCF margin36.2%+18.4pp

Returns & leverage

See full

Return on equity-45.6%-66.1pp

Debt / equity0×0.0×

Current ratio9×+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s long-term marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s long-term marketable securities?: Stoke Therapeutics, Inc. (STOK) reported long-term marketable securities of $67.48M in Q1 2026.
How has Stoke Therapeutics, Inc.'s long-term marketable securities changed year-over-year?: Stoke Therapeutics, Inc.'s long-term marketable securities increased by 193.5% year-over-year, from $22.99M to $67.48M.